Enfuvirtide Acetate (T-20)
Alias:Fuzeon
Reeks:CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
Casnr. : 159519-65-0
Moleculaire formule : C204H301N51O64
Moleculair gewicht : 4492
Zuiverheid (HPLC) : 98.0%min.
Verschijning : White to off-white amorphous solid
Enkele onzuiverheid (HPLC) : 0.5%maximaal
Aminozuursamenstelling : ±10% van theoretisch
Peptide-inhoud (N%) : ≥80,0%
Waterinhoud (Karel Fischer) : ≤8,0%
TrifluoroAcetate Content(HPIC) : ≤12.0%
MEVROUW (ESI) : Consistent
Massabalans : 95.0~105,0%
Cijfer : Farmaceutische kwaliteit
Opslag: Gesloten, onderstaand 2 ~ 8℃ behoud
Gebruik : Treatment option for patients suffering from HIV/AIDS.
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.
Enfuvirtide (HERBERG) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
